![](/wp-content/uploads/2024/05/Screenshot-2024-05-09-at-6.12.16%E2%80%AFPM.png)
$599
Novo Partners with Metaphore for Next-Gen Obesity Assets; Altimmune, Xeris, MannKind, and Viatris Q1 ’24 Earnings
A series of cardiometabolic-related news items have been observed from Novo Nordisk/Metaphore Biotechnologies, Altimmune, Xeris, MannKind, and Viatris. Below, FENIX provides highlights and insights for the respective news items.